A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 04 May 2017
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone; Prednisolone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS
- Sponsors Amgen; Onyx Pharmaceuticals
- 23 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 13 Aug 2014 Top-line results published in Amgen and Onyx Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History